ALDH7A1 and heart failure: Our prediction of toxicity and reduced inotropic response was borne out in clinical trials despite the considerable fanfare afforded to milrinone at the American Heart Association for the use of PDE inhibitors as a new class of agents to be used as clinical tools to treat heart failure [123,124].